瑞卡帕布杂质 | 283173-74-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 瑞卡帕布杂质
• 英文名称: 2-(4-formylphenyl)-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-one
• 英文别名: 4-(1-oxo-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-5-yl)benzaldehyde；4-(9-oxo-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-2-yl)benzaldehyde
• CAS: 283173-74-0
• 化学式: C₁₈H₁₄N₂O₂
• 分子量: 290.321
• InChiKey: HILFTUQIPUZDQL-UHFFFAOYSA-N

物化性质

• 熔点：
  238-240 °C (decomp)
• 沸点：
  657.0±55.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  62
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二甲胺 、 瑞卡帕布杂质 在 盐酸 、 sodium cyanoborohydride 、 zinc(II) chloride 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以72%的产率得到2-(4-(N,N-dimethylamino)methylphenyl)-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-one
  参考文献：
  名称：

  Novel Tricyclic Poly(ADP-ribose) Polymerase-1 Inhibitors with Potent Anticancer Chemopotentiating Activity:  Design, Synthesis, and X-ray Cocrystal Structure

  摘要：

  A series of novel compounds have been designed that are potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1), and the activity and physical properties have been characterized. The new structural classes, 3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-6-ones and 3,4-dihydropyrrolo[4,3,2-de]isoquinolin-5-(1H)-ones, have conformationally locked benzamide cores that specifically interact with the PARP-1 protein. The compounds have been evaluated with in vitro cellular assays that measure the ability of the PARP-1 inhibitors to enhance the effect of cytotoxic agents against cancer cell lines.

  DOI：

  10.1021/jm020259n
• 作为产物：
  描述：

  3-吲哚丙酸 在 aluminum (III) chloride 、 四(三苯基膦)钯 、 正丁基锂 、 氯化亚砜 、 盐酸羟胺 、 水 、 sodium acetate 、 sodium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 氯乙酰氯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 50.5h， 生成 瑞卡帕布杂质
  参考文献：
  名称：

  Poly(ADP-ribose) Polymerase in Neurodegeneration: Radiosynthesis and Radioligand Binding in ARC-SWE tg Mice

  摘要：

  We report the synthesis, radiosynthesis, and characterization of a radioligand for poly(ADP-ribose) polymerase (PARP). PARP is of central importance in cell homeostasis, neuroplasticity, and neurodegeneration in the brain. A radiolabeled PARP inhibitor was developed and used for autoradiographic quantification of PARP protein concentration in wild-type and transgenic rodent brains ex vivo in high resolution. The binding of [H-3]rucaparib was found to be confined to PARP-expressing domains, for example, cerebellar cortex or hippocampal regions in both models. Saturation binding experiments confirmed selective and reversible binding to a single site (K-d = 1.1 +/- 0.2 nM).

  DOI：

  10.1021/acschemneuro.8b00053

文献信息

• Copper-Mediated Radiosynthesis of [¹⁸F]Rucaparib
  作者：Zijun Chen、Gianluca Destro、Florian Guibbal、Chung Ying Chan、Bart Cornelissen、Véronique Gouverneur

  DOI：10.1021/acs.orglett.1c02770

  日期：2021.9.17

  poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is used in the clinic to treat BRCA-mutated cancers. Herein, we report two strategies to access the 18F-isotopologue of rucaparib by applying a copper-mediated nucleophilic 18F-fluorodeboronation. The most successful approach features an aldehydic boronic ester precursor that is subjected to reductive amination post-18F-labeling and affords [18F]rucaparib

  聚（ADP-核糖）聚合酶（PARP）抑制剂rucaparib在临床上用于治疗BRCA突变的癌症。在此，我们报告了两种通过应用铜介导的亲核18 F-氟脱硼来获得 rucaparib 的18 F-同位素体的策略。最成功的方法是采用醛硼酸酯前体，在18 F 标记后进行还原胺化，得到 [ 18 F]rucaparib，其活性产率为 11% ± 3% ( n = 3) 和摩尔活性 ( A m ) 高达 30 GBq/μmol。提出了初步体外研究。
• CRYSTALLINE OF CAMPHORSULFONIC ACID SALT OF RUCAPARIB AND METHOD OF PREPARING OF TRICYCLIC COMPOUNDS, RUCAPARIB AND CRYSTALLINE OF CAMPHORSULFONIC ACID SALT OF RUCAPARIB
  申请人：Formosa Laboratories, Inc.

  公开号：US20200165261A1

  公开（公告）日：2020-05-28

  A method of preparing a tricyclic compound of formula (I), comprising the step of converting a compound of formula (II) into a compound of formula (III); and hydrogenating the compound of formula (III) in the presence of hydrogenation catalyst and hydrogen to form the tricyclic compound of formula (I); wherein R 1 is H or a C 1-3 alkyl group; and R 2 is H, a halogen element or a C 1-3 alkyl group.

  一种制备化合物(I)的三环化合物的方法，包括将化合物(II)转化为化合物(III)的步骤；并在氢化催化剂和氢气的存在下氢化化合物(III)以形成化合物(I)的三环化合物；其中R1是H或C1-3烷基基团；R2是H、卤素元素或C1-3烷基基团。
• Tricyclic inhibitors of poly(ADP-ribose) polymerases
  申请人：Webber Evan Stephen

  公开号：US20050085460A1

  公开（公告）日：2005-04-21

  Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

  以下公式的化合物是聚(ADP核糖)转移酶（PARP）抑制剂，可用于治疗癌症和改善中风、头部创伤和神经退行性疾病的影响。作为癌症治疗药物，发明中的化合物可与细胞毒性药物和/或放射线联合使用。
• Crystalline of camphorsulfonic acid salt of rucaparib and method of preparing of tricyclic compounds, rucaparib and crystalline of camphorsulfonic acid salt of rucaparib
  申请人：Formosa Laboratories, Inc.

  公开号：US11021483B2

  公开（公告）日：2021-06-01

  A method of preparing a tricyclic compound of formula (I), comprising the step of converting a compound of formula (II) into a compound of formula (III); and hydrogenating the compound of formula (III) in the presence of hydrogenation catalyst and hydrogen to form the tricyclic compound of formula (I); wherein R1 is H or a C1-3 alkyl group; and R2 is H, a halogen element or a C1-3 alkyl group.

  一种制备式(I)三环化合物的方法，包括以下步骤：将式(II)化合物转化为式(III)化合物；在氢化催化剂和氢气存在下氢化式(III)化合物，形成式(I)三环化合物；其中 R1 为 H 或 C1-3 烷基；R2 为 H、卤素或 C1-3 烷基。
• TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1140936B1

  公开（公告）日：2004-03-17